Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
about
Safety, Tolerability, and Pharmacodynamics of ABT-122, a Tumor Necrosis Factor- and Interleukin-17-Targeted Dual Variable Domain Immunoglobulin, in Patients With Rheumatoid Arthritis.Bispecific antibodies: design, therapy, perspectives.Phase II Study of ABT-122, a Tumor Necrosis Factor- and Interleukin-17A-Targeted Dual Variable Domain Immunoglobulin, in Patients With Psoriatic Arthritis With an Inadequate Response to Methotrexate
P2860
Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Pharmacokinetics of ABT-122, a ...... lts from Three Phase I Trials.
@en
type
label
Pharmacokinetics of ABT-122, a ...... lts from Three Phase I Trials.
@en
prefLabel
Pharmacokinetics of ABT-122, a ...... lts from Three Phase I Trials.
@en
P2093
P2860
P1476
Pharmacokinetics of ABT-122, a ...... ults from Three Phase I Trials
@en
P2093
Amit Khatri
Heikki Mansikka
Ping Jiang
Sandra Goss
P2860
P2888
P304
P356
10.1007/S40262-017-0580-Y
P577
2018-05-01T00:00:00Z
P6179
1090892705